Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review

被引:8
作者
Njei, Basile [1 ,7 ]
Al-Ajlouni, Yazan A. [2 ]
Ugewndum, Derek [3 ]
Abdu, Manasik [4 ]
Forjindam, Anim [5 ]
Mohamed, Mouhand F. [6 ]
机构
[1] Yale Sch Med, Int Med Program, Sect Digest Dis, New Haven, CT USA
[2] New York Med Coll, Sch Med, Valhalla, NY USA
[3] Richmond Univ Med Ctr, Staten Isl, NY USA
[4] SUNY Buffalo, Dept Internal Med, Catholic Hlth Syst, Buffalo, NY USA
[5] Case Western Reserve Univ, Dept Physiol & Biophys, Med Physiol Program, Sch Med, Cleveland, OH USA
[6] Brown Univ, Dept Med, Providence, RI USA
[7] Yale Sch Med, Int Med Program, Sect Digest Dis, Wing Bldg 35A,Fl 2,Rm 210, West Haven, CT 06516 USA
关键词
Non-alcoholic fatty liver disease (NAFLD); lean individuals; genetics; epigenetics; systematic review; CONFERS SUSCEPTIBILITY; RISK; ASSOCIATION; VARIANT;
D O I
10.21037/tgh-23-31
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is common in obese individuals, but its occurrence in lean individuals and the underlying mechanisms are not well understood. This study aimed to systematically review the literature on the genetic and epigenetic factors influencing NAFLD in lean individuals.Methods: A comprehensive search was conducted on April 2nd, 2023, in seven databases using specific criteria. Only peer-reviewed studies in English, focusing on genetic or epigenetic effects on NAFLD in lean individuals, were included for qualitative synthesis. The Newcastle Ottawa Scale (NOS) was used for quality assessment. This study is registered with PROSPERO (CRD42023413809).Results: Following PRISMA guidelines, 18 studies were included in this review. The studies were conducted globally, with varying sample sizes and study designs. The NOS quality assessment revealed a moderate overall quality with variations in risk of bias and limitations in comparability and ascertainments of exposure among contributing studies. Genetic determinants related to lipid metabolism, inflammation, and oxidative stress pathways were identified, including PNPLA3 and TM6SF2 gene variants associated with increased NAFLD risk in lean individuals. Epigenetic modifications, particularly depletion of histone variants, were also implicated. However, some studies found no significant associations between genetic or clinical characteristics and lean NAFLD. Less frequent genetic risk factors, such as CETP and APOC3 gene variants, were reported.Conclusions: This systematic review underscores the importance of investigating genetic and epigenetic factors in lean NAFLD. The findings highlight the role of PNPLA3 and TM6SF2 gene variants and suggest potential epigenetic contributions. Further research is needed to fully understand the genetic and epigenetic mechanisms underlying NAFLD in lean individuals.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review
    Yifang Li
    Xuetao Wang
    Jun Zhang
    Shanshan Zhang
    Jian Jiao
    Reviews in Endocrine and Metabolic Disorders, 2022, 23 : 387 - 400
  • [22] Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis
    Bandyopadhyay, Sanjay
    Samajdar, Shambo Samrat
    Das, Saibal
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (07)
  • [23] Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease
    Hudert, Christian A.
    Selinski, Silvia
    Rudolph, Birgit
    Blaeker, Hendrik
    Loddenkemper, Christoph
    Thielhorn, Ria
    Berndt, Nikolaus
    Golka, Klaus
    Cadenas, Cristina
    Reinders, Joerg
    Henning, Stephan
    Bufler, Philip
    Jansen, Peter L. M.
    Holzhuetter, Hermann-Georg
    Meierhofer, David
    Hengstler, Jan G.
    Wiegand, Susanna
    LIVER INTERNATIONAL, 2019, 39 (03) : 540 - 556
  • [24] Dietary and genetic determinants of non-alcoholic fatty liver disease in coronary heart disease patients
    Heerkens, Luc
    Geleijnse, Johanna M.
    van Duijnhoven, Franzel J. B.
    EUROPEAN JOURNAL OF NUTRITION, 2024, 63 (05) : 1847 - 1856
  • [25] The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
    George, Elena S.
    Sood, Surbhi
    Kiss, Nicole
    Daly, Robin M.
    Nicoll, Amanda J.
    Roberts, Stuart K.
    Baguley, Brenton J.
    CURRENT ONCOLOGY, 2023, 30 (01) : 48 - 74
  • [26] Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kosmalski, Marcin
    Drzewoski, Jozef
    Szymczak-Pajor, Izabela
    Zieleniak, Andrzej
    Mikolajczyk-Solinska, Melania
    Kasznicki, Jacek
    Sliwinska, Agnieszka
    BIOMEDICINES, 2022, 10 (09)
  • [27] Non-alcoholic fatty liver disease (NAFLD) in lean individuals-Single centre large cohort clinicopathologic and immunophenotypic study
    Rastogi, Archana
    Rath, Indira
    Varadarajan, Annapoorani
    Ramakrishna, Gayatri
    Bihari, Chhagan
    Maiwall, Rakhi
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 238
  • [28] Shifting perspectives - interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals
    Bilic-Curcic, Ines
    Berkovic, Maja Cigrovski
    Virovic-Jukic, Lucija
    Mrzljak, Anna
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (01) : 80 - 93
  • [29] Cardiac Arrhythmias and Electrocardiogram Modifications in Non-Alcoholic Fatty Liver Disease. A Systematic Review
    Ismaiel, Abdulrahman
    Colosi, Horatiu A.
    Rusu, Flaviu
    Dumitrascu, Dan L.
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2019, 28 (04) : 483 - +
  • [30] Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
    Tacke, Frank
    Weiskirchen, Ralf
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)